Akhil Abraham Saji, MD

Akhil Abraham Saji, MD, is a urologist specializing in minimally invasive surgery and urologic oncology with an interest in technology-driven innovation within health care.

Articles by Akhil Abraham Saji, MD

Akhil Abraham Saji, MDProstate Cancer | September 27, 2023
Patients considering PC screening should talk to their PCP or urologist about the benefits and risks of identifying PC early.
Read More
Akhil Abraham Saji, MDLocalized Prostate Cancer | September 5, 2023
The da Vinci Single Port platform allows robot-assisted surgical procedures with the same precision as multiport techniques.
Akhil Abraham Saji, MDProstate Cancer | September 5, 2023
Increasing competition in robot-assisted surgical platform production will increase accessibility for patients everywhere.
Akhil Abraham Saji, MDNext-Generation Imaging | July 31, 2023
PSMA PET imaging is a leap forward in the fight to cure prostate cancer, especially as theranostic capabilities expand.
Akhil Abraham Saji, MDLocalized Prostate Cancer | July 31, 2023
What role can artificial intelligence play in the diagnosis and management of prostate cancer utilizing MRI?
Akhil Abraham Saji, MDAUA 2023 | May 31, 2023
One might assume that the AUA meeting is geared toward practicing urologists, but it is also crucial for urologic trainees.
Akhil Abraham Saji, MDLocalized Prostate Cancer | May 30, 2023
The postsurgical treatment of functional outcomes such as UI and ED after SRP remains a challenge for all urologists.
Akhil Abraham Saji, MDNon-Muscle Invasive Urothelial Carcinoma | May 30, 2023
FDA approval of Adstiladrin for use in BCG-unresponsive NMIBC expands the armamentarium for treatment of high-risk NMIBC.
David Ambinder, MDAUA 2023 | May 2, 2023
Drs. David Ambinder and Akhil Saji highlight the importance of attending the AUA meeting as urology residents.
Akhil Abraham Saji, MDNon-Muscle Invasive Urothelial Carcinoma | May 1, 2023
NMIBC-associated costs vary widely across types of treatments utilized, health systems, and regions of the country.
Akhil Abraham Saji, MDMuscle Invasive Urothelial Carcinoma | May 1, 2023
The minimally invasive options available to patients diagnosed with muscle-invasive disease of urothelial origin are limited.
Akhil Abraham Saji, MDProstate Cancer | March 31, 2023
This review highlights the existing research regarding the financial toxicity of advanced prostate cancer.
Akhil Abraham Saji, MDAUA 2023 | March 30, 2023
This review highlights the upcoming plenary sessions of importance in prostate, bladder, kidney, and testicular cancer.
Akhil Abraham Saji, MDLocalized Renal Cell Carcinoma | March 30, 2023
AUA guidelines for localized RCC have thermal ablation as an alternative modality. EAU guidelines are conflicting.
Akhil Abraham Saji, MDProstate Cancer | March 10, 2023
Mutahar Ahmed, MD, discusses the history and current applications of single-port robotic surgery in prostate cancer.
Akhil Abraham Saji, MDLocalized Prostate Cancer | February 28, 2023
This review highlights the research on the costs related to the treatment of localized PC and the associated outcomes.
Akhil Abraham Saji, MDNon-Muscle Invasive Urothelial Carcinoma | February 24, 2023
BCG plus nogapendekin alfa inbakicept may offer an enhanced treatment option for patients with high-risk NMIBC.
Akhil Abraham Saji, MDProstate Cancer | January 13, 2023
A review of the GÖTEBORG-2 trial and the current recommendations for utilizing mpMRI in prostate cancer screening, ...
Akhil Abraham Saji, MDUrothelial Carcinoma | January 13, 2023
An investigation and review of both studies regarding their differences, similarities, and conclusions.
Akhil Abraham Saji, MDProstate Cancer | January 13, 2023
The evidence regarding bisphosphate and denosumab therapy and the impact that bone-protective agents can have on patients.